Assessments
Normal Control
Diabetic Control
Feno
per se
Saxa
per se
Feno Treated Diabetic Group
Saxa Treated Diabetic Group
Feno + Saxa Treated Diabetic Group
Lisino Treated Diabetic Group
Glucose (mg/dl)
101.93 ± 10.88
367.98 ± 35.68
a
101.96 ± 14.98
104.10 ± 11.28
354.23 ± 40.72
299.98 ± 34.17
b
294.98 ± 32.56
b
336.73 ± 36.72
Total Cholesterol (mg/dl)
58.08 ± 7.41
86.06 ± 11.21
a
58.67 ± 6.42
57.15 ± 6.72
65.16 ± 7.62
b
83.58 ± 9.56
64.31 ± 8.36
b
81.08 ± 10.50
Triglycerides (mg/dl)
95.75 ± 10.10
189.29 ± 19.20
a
95.32 ± 12.82
95..81 ± 11.74
122.15 ± 17.53
b
178.31 ± 19.39
115.38 ± 16.83
b
158.75 ± 16.04
b
High Density Lipoproteins (mg/dl)
35.81 ± 3.86
26.18 ± 3.27
a
36.83 ± 4.28
36.23 ± 3.34
35.05 ± 4.35
b
27.99 ± 3.67
37.77 ± 4.32
b
30.39 ± 2.85
Table 1:
Effect of fenofibrate (feno), saxagliptin (saxa) and lisinopril on serum glucose and lipid profile. All values are represented as mean ± SD. a=p< 0.05 versus normal control; b=p< 0.05 versus diabetic control.
